Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.49 |
| ▸ | NOS2 | P35228 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 6/20 | 0.47 |
| ▸ | NOS3 | P29474 | 5/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL16486916 | 1.00 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28165841 | 1.00 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL15890 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL15889 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL27996908 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28725103 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL2729038 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL4331631 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1128244 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL4332185 | 0.98 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102625690-B | Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof | COLGATE PALMOLIVE CO | 2014-11-26 | — | — | CN | claimed |
| CN-102625690-A | Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof | COLGATE PALMOLIVE CO | 2012-08-01 | — | — | CN | claimed |
| EP-2413885-A2 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF | Colgate-Palmolive Company (US) | 2012-02-08 | — | — | EP | claimed |
| US-20120020899-A1 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2012-01-26 | — | — | US | claimed |
| WO-2010115041-A2 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2010-10-07 | — | — | WO | claimed |
| EP-2432444-B1 | ORAL COMPOSITIONS CONTAINING POLYGUANIDINIUM COMPOUNDS AND METHODS OF MANUFACTURE AND USE THEREOF | COLGATE PALMOLIVE CO (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-105412143-A | Oral cavity composition containing polyguanidine compounds and preparation and application method of oral cavity composition | COLGATE PALMOLIVE CO | 2016-03-23 | — | — | CN | disclosed |
| CN-102625690-B | Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof | COLGATE PALMOLIVE CO | 2014-11-26 | — | — | CN | disclosed |
| US-8758729-B2 | Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof | COLGATE-PALMOLIVE COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| CN-102625690-A | Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof | COLGATE PALMOLIVE CO | 2012-08-01 | — | — | CN | disclosed |
| CN-102427795-A | Oral compositions containing polyguanidine compounds and methods of making and using the same | COLGATE PALMOLIVE CO | 2012-04-25 | — | — | CN | disclosed |
| EP-2432444-A1 | ORAL COMPOSITIONS CONTAINING POLYGUANIDINIUM COMPOUNDS AND METHODS OF MANUFACTURE AND USE THEREOF | Colgate-Palmolive Company (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120045400-A1 | ORAL COMPOSITIONS CONTAINING POLYGUANIDINIUM COMPOUNDS AND METHODS OF MANUFACTURE AND USE THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2413885-A2 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF | Colgate-Palmolive Company (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20120020899-A1 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010134904-A1 | ORAL COMPOSITIONS CONTAINING POLYGUANIDINIUM COMPOUNDS AND METHODS OF MANUFACTURE AND USE THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010115041-A2 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045400-A1 | ORAL COMPOSITIONS CONTAINING POLYGUANIDINIUM COMPOUNDS AND METHODS OF MANUFACTURE AND USE THEREOF | SRM, GMPS, PARG | OTC 159/4885DDAH1 2839/4885NOS2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.